The Latest Analyst Ratings for Homology Medicines
Portfolio Pulse from Benzinga Insights
In the last quarter, Homology Medicines (NASDAQ:FIXX) received two bullish and two indifferent analyst ratings. Over the past three months, four analysts have offered 12-month price targets for the company, with an average price target of $7.62, representing a 10.35% decrease from the previous average price target of $8.50.
July 28, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Homology Medicines received mixed analyst ratings, with an average price target of $7.62, a decrease from the previous target.
The decrease in the average price target suggests that analysts have a less optimistic outlook for the company, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100